ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS | REFER A PATIENT
Menu
Your participation makes a difference.
As a ROADS Clinical Study participant, you will receive a proven safe and effective treatment, and your care will be closely monitored by a physician and the medical research team. In addition, you’ll be making an important contribution to future patients with brain tumors by helping to ensure they also receive the best possible treatment.
The ROADS Study is sponsored by GT Medical Technologies, Inc., the makers of GammaTile. Please discuss the risks and benefits of participating in this clinical study with your care team.
Indications
GammaTile is indicated to deliver radiation therapy in patients with newly diagnosed malignant and recurrent brain tumors. Possible complications can occur with any neurosurgical procedure and include cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation. For full product and safety information, speak to your physician and refer to the instructions for use.
ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS
ENROLLING NOW
©2022 GT Medical Technologies, Inc. I All rights reserved I GammaTile is a registered trademark of GT Medical Technologies, Inc.